Sanofi pulls the plug on ADC after lung cancer PhIII disappoints

The on­ly clin­i­cal-stage an­ti­body-drug con­ju­gate in Sanofi’s pipeline has flunked a Phase III study, push­ing the French drug­mak­er to wind down the en­tire de­vel­op­ment pro­gram.

At an in­ter­im analy­sis, the ADC failed to meet the dual pri­ma­ry end­point of im­prov­ing pro­gres­sion-free sur­vival com­pared to do­c­etax­el in sec­ond-line metasta­t­ic non-squa­mous non-small cell lung can­cer. All pa­tients in the tri­al have tu­mors that ex­press high lev­els of car­ci­noem­bry­on­ic anti­gen-re­lat­ed cell ad­he­sion mol­e­cule 5 (CEA­CAM5), which the drug, tusami­ta­m­ab rav­tan­sine, is di­rect­ed against.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.